Inhibition of topoisomerase II does not inhibit transcription of RNA polymerase I and II genes.
Injection of VM-26 (teniposide) into Xenopus oocytes inhibits the activity of topoisomerase II but does not inhibit transcription by RNA polymerases I and II. A specific assay for topoisomerase II, resolution of catenated DNA molecules into product rings, was used to quantitate VM-26 inhibition in vivo. When catenanes were injected without VM-26, about 60% of them were separated into product rings in the first 5 min after injection, and decatenation of the remainder was complete within 15 min. When VM-26 was coinjected, 60% of the catenanes were separated into product rings in the first 5 min after injection, but the remaining 40% were stable over the next 40 min. At 1 h after injection catenanes were no longer detected in the gel analysis, but the increasing numbers of linear product rings indicated that topoisomerase II continued to be inhibited by VM-26. These results suggest that a short lag of approximately 5 min is required for VM-26 to inhibit topoisomerase II and that after this initial period topoisomerase II is inhibited by more than 90%. There was no detectable decrease in transcription of injected rRNA and thymidine kinase (TK) genes or in the activity of the rRNA enhancer when these transcription templates were coinjected with VM-26. The time required for assembly of injected DNA into chromatin doubled in the presence of VM-26.
Dunaway
M
M
Department of Molecular and Cell Biology, University of California, Berkeley 94720.
D000818:Animals; D002843:Chromatin / Q000187:drug effects / Q000378:metabolism / Q000648:ultrastructure; D005260:Female; D005796:Genes / Q000187:drug effects; D007700:Kinetics; D009865:Oocytes / Q000187:drug effects / Q000201:enzymology; D010957:Plasmids; D011034:Podophyllotoxin / Q000031:analogs & derivatives*; D012318:RNA Polymerase I / Q000235:genetics*; D012319:RNA Polymerase II / Q000235:genetics*; D012335:RNA, Ribosomal / Q000187:drug effects / Q000235:genetics; D011995:Recombination, Genetic; D013713:Teniposide / Q000494:pharmacology*; D013937:Thymidine Kinase / Q000235:genetics; D059005:Topoisomerase II Inhibitors; D014158:Transcription, Genetic / Q000187:drug effects; D014982:Xenopus laevis
D002843:Chromatin; D012335:RNA, Ribosomal; D059005:Topoisomerase II Inhibitors; D013713:Teniposide; D013937:Thymidine Kinase; D012319:RNA Polymerase II; D012318:RNA Polymerase I; D011034:Podophyllotoxin